US 12,221,469 B2
Switch receptors using IL-9 signaling domains
John Connolly, Red Oak, TX (US); Sean Parker, San Francisco, CA (US); and Kenan Christopher Garcia, San Francisco, CA (US)
Assigned to PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY, San Francisco, CA (US); and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Filed by Parker Institute for Cancer Immunotherapy, San Francisco, CA (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Jun. 2, 2023, as Appl. No. 18/328,473.
Application 18/328,473 is a continuation of application No. 17/946,894, filed on Sep. 16, 2022, abandoned.
Claims priority of provisional application 63/245,661, filed on Sep. 17, 2021.
Prior Publication US 2023/0303661 A1, Sep. 28, 2023
Int. Cl. C12N 5/071 (2010.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01); C07K 14/71 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01)
CPC C07K 14/7155 (2013.01) [C07K 14/70578 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464406 (2023.05); A61K 39/464419 (2023.05); A61K 39/464474 (2023.05); A61K 2239/23 (2023.05); A61K 2239/53 (2023.05); A61K 2239/59 (2023.05); C07K 14/70503 (2013.01); C07K 14/70521 (2013.01); C07K 14/71 (2013.01); C07K 2319/03 (2013.01); C07K 2319/32 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01)] 20 Claims
 
1. A recombinant nucleic acid molecule encoding a chimeric receptor, said chimeric receptor comprising:
an extracellular portion comprising a binding domain of an endogenous cytokine receptor, wherein the extracellular portion does not bind IL-9;
an intracellular portion comprising an endodomain of an IL-9 receptor; and
a transmembrane domain that joins the extracellular portion and the intracellular portion, wherein the chimeric receptor induces signaling through the IL-9 endodomain upon extracellular ligand binding, and wherein the chimeric receptor comprises an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from SEQ ID Nos: 63-80.